June 1, 2010
Tetraphase Closes $45 Million Series C Financing. Company to advance novel antibiotics into clinical development to address serious drug-resistant, gram-negative infections.

April  29, 2010
Tetraphase Announces Participation in Session on New Treatments for Multidrug Resistant Gram-Negative Bacteria at 2010 BIO Internat ional Convention.

October 06, 2009
Tetraphase Pharmaceuticals Completes Series B Financing to Support the Advancement of Novel Antibiotic Drug Candidates.

September 10, 2009
Tetraphase Pharmaceuticals Presents Study for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009.

August 06, 2008
Tetraphase Pharmaceuticals Completes Series A Financing to Support the Advancement of Breakthrough Synthetic Chemistry Platform.

November 24, 2006
Tetraphase Pharmaceuticals Formed to Advance Breakthrough, Harvard-Developed Synthesis Technology for New Antibiotics to Treat Drug-Resistant Bacterial Infections.